Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sigyn Therapeutics, Inc. (SIGY)
San Diego, CA, US
Sigyn Therapeutics, Inc. operates as a therapeutic technology enterprise currently in its development phase. The company's core innovation is Sigyn Therapy, an advanced blood purification system designed to overcome the limitations of existing drugs and medical devices used to treat severe inflammatory disorders. A key focus is on sepsis, which represents a major cause of hospital-related deaths. Furthermore, Sigyn Therapeutics is actively evaluating the potential of Sigyn Therapy to address a broad spectrum of other therapeutic targets, including bacterial endotoxins, peptidoglycan, and lipoteichoic acid; various viral pathogens; harmful hepatic toxins; CytoVesicles; and significant pro-inflammatory cytokines such as tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6. The company is headquartered in San Diego, California.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.89% | -10.26% | -20.45% | -30.00% | -98.25% | -97.95% | -98.59% | -65.00% | -97.20% | -97.59% | -97.59% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+33.4% ★ Q3'25: +61.7% (vs Q3'24)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q3'25: +72.3% (vs Q3'24)
-
Share dilution Biotechnology: -3.4%+21.1% Q3'25: +26.5% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.87× Q3'25: -1.22× (vs Q3'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 EPS Ana. |
Dec 2031 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.80M
est: 44.0K (+4,001.3%)
|
1.28M
est: 1.97M (-34.9%)
|
28.3K
est: 6.91M (-99.6%)
|
143.3K
est: 15.28M (-99.1%)
|
—
est: 26.16M (-100.0%)
|
—
est: 44.0K (-100.0%)
|
1.97M
est.
|
6.91M
6.91M – 6.91M
+250.3% YoY
|
15.28M
15.28M – 15.28M
+121.3% YoY
|
26.16M
26.16M – 26.16M
+71.2% YoY
|
26.16M
26.16M – 26.16M
+0.0% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| EBITDA |
-549.4K
|
-2.82M
|
-1.70M
|
73.8K
|
-905.1K
|
-2.52M
|
—
est.
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-635.9K
|
-3.05M
|
-1.95M
|
-1.6K
|
-916.4K
|
-3.34M
|
—
est.
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-831.5K
est: -879.42M (+99.9%)
|
-4.25M
est: -559.63M (+99.2%)
|
-2.62M
est: -399.74M (+99.3%)
|
-3.13M
est: 79.95M (-103.9%)
|
-1.60M
est: 719.52M (-100.2%)
|
-3.34M
est: -879.42M (+99.6%)
|
-559.63M
est.
|
-399.74M
-399.74M – -399.74M
+28.6% YoY
|
79.95M
79.95M – 79.95M
+120.0% YoY
|
719.52M
719.52M – 719.52M
+800.0% YoY
|
-3.20M
-3.20M – -3.20M
-100.4% YoY
|
-3.73M
-3.73M – -3.73M
-16.7% YoY
|
-3.73M
-3.73M – -3.73M
+0.0% YoY
|
| SGA |
1.48M
|
3.21M
|
1.02M
|
625.6K
|
889.0K
|
1.75M
|
—
est.
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-4.64
est: -660.00 (+99.3%)
|
-13.54
est: -420.00 (+96.8%)
|
-6.04
est: -300.00 (+98.0%)
|
-5.78
est: 60.00 (-109.6%)
|
-0.22
est: 540.00 (-100.0%)
|
-2.51
est: -660.00 (+99.6%)
|
-420.00
est.
|
-300.00
-300.00 – -300.00
+28.6% YoY
|
60.00
60.00 – 60.00
+120.0% YoY
|
540.00
540.00 – 540.00
+800.0% YoY
|
-2.40
-2.40 – -2.40
-100.4% YoY
|
-2.80
-2.80 – -2.80
-16.7% YoY
|
-2.80
-2.80 – -2.80
+0.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Capital Master Fund Ltd. | 7.07M | 9.99% | 7.07M | — | 7.07M | — | CO | Cayman Islands | 2019-02-04 | ↗ |
| 2 | Alpha Capital Anstalt | 4.38M | 9.99% | 4.38M | — | 4.38M | — | CO | Liechtenstein | 2017-02-14 | ↗ |
| 3 | Capital Management LLC | 4.34M | 9.99% | 4.34M | — | 4.34M | — | CO | United States | 2017-02-02 | ↗ |
| 4 | Brio Capital Management LLC | 3.73M | 9.99% | 3.73M | — | 3.73M | — | CO | Delaware, United States | 2022-02-04 | ↗ |
| 5 | Brio Capital Master Fund Ltd. | 3.73M | 9.99% | 3.73M | — | 3.73M | — | CO | Cayman Islands | 2022-02-04 | ↗ |
| 6 | Osher Capital Partners LLC | 3.42M | 9.99% | 3.42M | — | 3.42M | — | CO | New York | 2020-10-29 | ↗ |
| 7 | Crossover Capital Fund I, LLC (1) | 1.92M | 3.70% | 1.92M | — | — | — | OO | WA | 2018-03-02 | ↗ |
| 8 | Crossover Capital Fund II, LLC (1) | 1.92M | 3.70% | 1.92M | — | — | — | OO | WA | 2018-03-02 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| James A. Joyce | Co-Founder, Chairman, Chief Executive Officer, Inventor & Interim Chief Financial Officer | 507.7K | male |
| Craig Roberts | Co-Founder, Chief Technology Officer & Director | 171.6K | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SIGY
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
